Clinical Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma

临床核心：IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性

基本信息

批准号：
10589805
负责人：
MICHAEL E PICHICHERO
金额：
$ 30.47万
依托单位：
BOSTON CHILDREN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-03-10 至 2027-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10589805
关键词：
3 year old Adjuvant Africa Age Antibody Response Asthma Canada Child Child Health Clinical Clinical Trials Communicable Diseases Data Development Disease Functional disorder Future Geography Goals Growth Health Hypersensitivity Immune Immune System Diseases Immune response Immune system Immunologic Memory Immunologics Immunology procedure Impairment Incidence Infant Infection Infection prevention Intervention Intestines Investigation Lead Life Longitudinal cohort study Measures Modernization Molecular Mucous Membrane Nasopharynx Papua New Guinea Phenotype Population Predisposition Prospective cohort Proteins Proteomics Respiratory Tract Infections Sampling Secure Shapes Systems Biology Testing Vaccination Vaccines Validation Variant biobank biomarker development biomarker discovery clinical phenotype cohort data exchange early childhood immune modulating agents metabolomics microbiome research mortality multiple omics predictive marker prevent prospective recruit respiratory tool transcriptomics vaccine response vaccine-induced antibodies

项目摘要

Project Summary/Abstract – Clinical Core (CC) The Clinical Core (CC) will provide and coordinate sharing of existing biorepository and new prospective clinical samples collected from the systemic and mucosal (intestinal and nasopharyngeal) compartments from past and ongoing early childhood cohorts to enable characterization of vaccine response-specific, respiratory infection- specific, and asthma-specific OMIC signatures and endotypes. These discoveries will inform interventions that may redirect unfavorable IDEAL endotypes associated with disease to those associated with health. Specifically, the CC will: 1. Coordinate transfer of biorepository clinical samples from the four early life cohorts (EPIC-HIPC, VDAART, Rochester Combined Cohort (RCC), and CHILD) that together will comprise our IDEAL Meta Cohort (IMC) to Cores/Projects for OMIC and immune assays; 2. Measure vaccine induced antibody levels in VDART and CHILD cohorts; and 3. Recruit a well-defined prospective infant cohort to provide new samples for validation testing, confirm predictive biomarkers, test mechanistic hypotheses, identify immunomodulatory agents (e.g., proteins, metabolites, adjuvants or vaccines) overcoming impaired phenotype, and secure a new biorepository for future investigations.

项目摘要/摘要 - 临床核心（CC）临床核心（CC）将提供并协调现有的生物库和新的前瞻性临床共享从过去和正在进行的幼儿同时组能够表征疫苗反应特异性，呼吸道感染的表征特异性和哮喘特异性的奥马克特征和内型。这些发现将告知干预措施可能会将与疾病相关的不利理想内型重新定向到与健康相关的疾病。具体来说， CC将： 1。从四个早期人群中的生物疗法临床样品的坐标转移（Epic-ihip，vdaart，罗切斯特（Rochester）组合队列（RCC）和儿童）一起将我们的理想元组（IMC）完成 OMIC和免疫测定的核心/项目； 2。测量VDART和儿童队列中疫苗诱导的抗体水平；和 3。招募一个定义明确的潜在婴儿队列以提供新样本进行验证测试，请确认预测性生物标志物，测试机械假设，鉴定免疫调节剂（例如蛋白质，代谢物，调节剂或阴道）克服了表型受损，并确保将来的新生物座调查。